Maintaining completion rates during the vaccination rollout for COVID-19
The rollout of the COVID-19 vaccines is gaining momentum, and has the potential to help the global population move beyond the current pandemic, however, there is the potential for the rollout to impact clinical trials. In this webinar, we will look at the challenges of continuing clinical trials during the rollout period to produce reliable data, while also maintaining the health and safety of participants as the number one priority.
As the vaccine rollout continues, it is anticipated that it will have an effect on completion levels for clinical trial participants, particularly where any medical indications from the vaccine may mask or be attributed to the pharmaceutical being studied.
By increasing communication channels and frequency, as well as developing strategies around crossover trials and offering alternative locations with different vaccine rollout stages in the population, much of these challenges can be addressed.
This webinar shows how Nucleus Network is meeting this challenge, and how it can assist or complement clients conducting trials at this time.
Presented by
Cameron Johnson,
Chief Executive Officer
One of Australia’s leading Phase 1 clinical trial professionals, Cameron Johnson joined Nucleus Network in 2013 as Chief Operating Officer before stepping into the role of CEO in 2016.
Under his leadership, Nucleus Network has expanded with the acquisition of clinical sites in Brisbane and the US to become the only Australian Phase 1 clinical trial organization with a presence in both Australia and the US.
Dr Trisha Shamp,
Senior Medical Officer
PhD Clinical Pharmacology, PA-C (Physician Assistant, NCCPA board certified) , Board certified Cardiovascular PA-C with American Board of Cardiovascular Medicine, Certified Surgical Physician Assistant with the NCCPA (National Academy of Physician Assistants).
Trisha has over 20 years of experience in conducting clinical research including comprehensive protocol writing for early phase programs, PK modeling, translational research, renal PK studies and advising biotech on FDA guidance for renal and hepatic PK studies and IND opening protocol creation. She is also a Teacher/mentor at medical and pharmacy programs
Dr Paul Griffin,
Principal Investigator
Dr. Paul Griffin is a Principal Investigator, and the Medical Director at Nucleus Network’s Brisbane site; where he has overseen more than 100 clinical trials, predominantly in Infectious Diseases. He is the Director of Infectious Diseases at Mater Health Services in Brisbane and Conjoint Associate Professor at the University of Queensland School of Medicine and Affiliate Associate Professor Mater Research Institute.
Jeff Wong,
Jeff joined Nucleus Network almost 15 years ago as a Clinical Research Co-ordinator, and has steadily progressed in the company, first to project management, then to business development where he now leads Nucleus Network’s BD department.
Jeff’s understanding of the practical realities of our clinical trial process, as well as an extensive knowledge of the industry allows him to ensure that Nucleus Network’s people are kept informed and trained to suit the latest developments in the needs and ambitions of the medical research sector, and that Nucleus Network can deliver on their promise of advancing medicine, improving lives.
